Moleculin Biotech (NASDAQ:MBRX) Issues Quarterly Earnings Results, Misses Estimates By $1.85 EPS

Moleculin Biotech (NASDAQ:MBRX) released its quarterly earnings data on Thursday. The company reported ($3.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($1.85), FiscalAI reports.

Moleculin Biotech Price Performance

Shares of NASDAQ:MBRX traded up $0.06 during midday trading on Thursday, hitting $2.20. The company had a trading volume of 260,781 shares, compared to its average volume of 166,559. The company has a market cap of $11.74 million, a price-to-earnings ratio of -0.07 and a beta of 1.74. Moleculin Biotech has a 12-month low of $1.79 and a 12-month high of $25.00. The company has a fifty day moving average of $2.34 and a two-hundred day moving average of $4.81.

Institutional Investors Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC acquired a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech at the end of the most recent reporting period. Institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MBRX. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Moleculin Biotech in a report on Tuesday, March 24th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Moleculin Biotech presently has a consensus rating of “Hold” and an average target price of $22.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.